Hereditary Angioedema Therapeutics Market to Grow with a CAGR of 8.89% through 2030
Increased
funding for rare genetic diseases and orphan drugs by governments and private
companies, coupled with the development of advanced HAE therapeutics, is
expected to drive the Global Hereditary Angioedema Therapeutics Market growth
in the forecast period, 2026-2030
According to
TechSci Research report, “Hereditary Angioedema Therapeutics Market – Global
Industry Size, Share, Trends, Competition Forecast & Opportunities, 2030F”,
the Global Hereditary Angioedema Therapeutics Market stood at USD 4.36 Billion in
2024 and is expected to reach USD 7.28 Billion by 2030 with a CAGR of 8.89% during
the forecast period. The global hereditary angioedema therapeutics market is
evolving rapidly due to advancements in treatment modalities and increasing
efforts to improve disease management. With a deeper understanding of the
genetic mechanisms underlying HAE, pharmaceutical firms are designing
innovative therapies that offer better disease control and improved quality of
life for patients. The introduction of next-generation therapies targeting
specific pathways involved in disease progression has led to a shift toward
personalized medicine. Growing physician awareness and improvements in
healthcare infrastructure are enabling faster diagnosis and treatment
initiation, reducing the frequency and severity of attacks. Regulatory agencies
are actively supporting drug development efforts by granting fast-track designations
and orphan drug status to promising pipeline candidates, further driving
innovation and commercialization.
The competitive
landscape is witnessing dynamic changes as companies focus on product
differentiation and treatment convenience. Drug manufacturers are prioritizing
non-invasive administration routes to enhance patient compliance and minimize
the need for frequent hospital visits. The demand for novel biologics and
gene-based therapies is increasing as researchers explore curative treatment
approaches. Mergers, acquisitions, and licensing agreements are becoming
prevalent strategies for firms looking to expand their market presence and
strengthen their research pipelines. The emphasis on real-world evidence and
post-marketing surveillance is shaping regulatory and clinical decision-making,
ensuring that newly introduced therapies align with patient needs and
healthcare system requirements. As industry players intensify efforts to refine
existing treatment options, the market is expected to see a surge in
competition and innovation.
The market is
well-positioned for expansion, with several untapped opportunities driving
future development. The rise of precision medicine and gene-editing
technologies opens the door for groundbreaking treatments that could
potentially offer long-term disease remission. Digital health solutions,
including AI-powered diagnostic tools and wearable monitoring devices, are
enhancing disease tracking and facilitating proactive treatment adjustments.
Expansion into underserved patient populations through targeted awareness
campaigns and improved diagnostic capabilities presents a significant avenue
for growth. As pharmaceutical companies explore combination therapies and
next-generation biologics, the market is expected to witness a steady influx of
innovative solutions catering to a broader spectrum of patient needs. These
factors collectively contribute to a dynamic and evolving market landscape with
promising prospects for the future.
Browse over XX market data Figures spread
through XX Pages and an in-depth TOC on "Global Hereditary Angioedema Therapeutics Market”
The Global Hereditary
Angioedema Therapeutics Market is segmented into drug class, distribution
channel, application, regional distribution, and company.
Based on the Application,
Prophylaxis emerged
as the fastest growing segment in the Global Hereditary Angioedema Therapeutics
Market during the forecast period. This is driven by the increasing demand for
long-term disease management solutions. HAE is a rare but life-threatening
genetic disorder characterized by recurrent episodes of severe swelling in
various body parts, including the airway, extremities, and gastrointestinal
tract. While acute treatments address individual attacks, the growing emphasis
on preventive therapies is fueling the demand for prophylactic treatments that
reduce attack frequency and severity. The rising adoption of prophylactic
therapies is largely due to advancements in targeted biologics and RNA-based
therapeutics that offer improved efficacy, better patient adherence, and a
reduced burden of frequent attacks. Regulatory approvals of C1 esterase
inhibitors, kallikrein inhibitors, and RNA-targeted drugs like donidalorsen
have revolutionized HAE prophylaxis, offering patients more reliable and
long-lasting treatment options. Additionally, the shift toward subcutaneous and
oral formulations enhances patient compliance compared to traditional
intravenous therapies.
Based
on the Region, Asia-Pacific emerged as the fastest growing region in the Global
Hereditary Angioedema Therapeutics Market during
the forecast period. This is driven by increasing disease awareness, rising
healthcare investments, and growing access to advanced therapies. Historically,
HAE has been underdiagnosed and undertreated in many Asia-Pacific countries due
to limited awareness among both patients and healthcare providers. However,
recent initiatives by governments, rare disease organizations, and
pharmaceutical companies have significantly improved early diagnosis and
treatment adoption across the region. Regulatory advancements and new product
approvals are accelerating market growth, with companies like Takeda, CSL
Behring, and Ionis Pharmaceuticals expanding their presence in the region. The
rising availability of prophylactic therapies, including C1 esterase
inhibitors, kallikrein inhibitors, and RNA-based drugs, has enhanced disease
management options, improving patient outcomes. Favorable reimbursement
policies and government support for rare disease treatments in countries like
Japan, China, and South Korea further contribute to the market’s rapid
expansion.
Additionally,
a growing healthcare infrastructure, increasing disposable incomes, and a
rising prevalence of genetic disorders are fueling demand for innovative HAE
therapeutics. With ongoing clinical trials and strategic collaborations,
Asia-Pacific is set to become a key market for advanced HAE treatments, driving
robust growth in the forecast period.
Major companies operating in Global Hereditary
Angioedema Therapeutics Market are:
- Shire plc
- Sanofi SA
- Pharming Healthcare Inc.
- Attune Pharmaceuticals
- Adverum Biotechnologies
- Arrowhead Pharmaceuticals
- Ionis Pharmaceuticals
- BioCryst Pharmaceuticals Inc.
- CSL Behring.
- CENTOGENE N.V
Download Free Sample Report
Customers can also request for 10%
free customization on this report
“The Global
Hereditary Angioedema Therapeutics Market is expanding due to the rising focus
on pediatric treatment options, addressing a critical gap in disease management
for younger patients. Historically, most therapies were designed for adults,
but recent advancements have led to the development and approval of
pediatric-specific treatments, ensuring early intervention and improved
long-term outcomes. Regulatory agencies are actively encouraging research in
this segment by granting pediatric exclusivity extensions and priority review
designations. The growing awareness among pediatricians and caregivers,
combined with an increasing number of clinical trials focusing on children, is
further accelerating market growth. This shift toward inclusive treatment
strategies is transforming hereditary angioedema management.,” said Mr. Karan
Chechi, Research Director of TechSci Research, a research-based management
consulting firm.
“Hereditary Angioedema
Therapeutics Market - Global Industry Size, Share, Trends, Opportunity, and
Forecast, Segmented By Drug Class (C1 Esterase Inhibitor, Selective Bradykinin
B2 Receptor Antagonist, Kallikrein Inhibitor, Other Drug Classes), By Distribution
Channel (Hospital Pharmacy, Retail Pharmacy, Other Distribution Channels), By
Application (Prophylaxis, On-demand), By Region and Competition, 2020-2030F”,
has evaluated the future growth potential of Global Hereditary Angioedema
Therapeutics Market and provides statistics & information on market size,
structure and future market growth. The report intends to provide cutting-edge
market intelligence and help decision makers take sound investment decisions.
Besides, the report also identifies and analyzes the emerging trends along with
essential drivers, challenges, and opportunities in Global Hereditary
Angioedema Therapeutics Market.
Contact
TechSci
Research LLC
420
Lexington Avenue, Suite 300,
New York,
United States- 10170
Tel: +1-332-258-6602
Email: sales@techsciresearch.com
Website: www.techsciresearch.com